Financial results - RENANS PHARMA SRL

Financial Summary - Renans Pharma Srl
Unique identification code: 23712687
Registration number: J40/6670/2008
Nace: 4646
Sales - Ron
152.019
Net Profit - Ron
47.321
Employees
2
Open Account
Company Renans Pharma Srl with Fiscal Code 23712687 recorded a turnover of 2024 of 152.019, with a net profit of 47.321 and having an average number of employees of 2. The company operates in the field of Comerţ cu ridicata al produselor farmaceutice și medicale having the NACE code 4646.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Renans Pharma Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 6.316 21.927 41.481 49.080 73.842 90.628 100.917 125.492 150.170 152.019
Total Income - EUR 16.303 20.884 39.915 73.105 152.197 112.769 126.328 168.417 184.314 186.624
Total Expenses - EUR 34.575 26.054 52.623 84.517 152.828 85.952 91.271 117.921 119.795 136.047
Gross Profit/Loss - EUR -18.272 -5.170 -12.708 -11.412 -631 26.818 35.057 50.497 64.519 50.578
Net Profit/Loss - EUR -18.462 -5.648 -13.129 -11.903 -1.369 25.983 34.049 49.267 63.225 47.321
Employees 1 2 2 2 2 1 1 2 2 2
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 1.8%, from 150.170 euro in the year 2023, to 152.019 euro in 2024. The Net Profit decreased by -15.551 euro, from 63.225 euro in 2023, to 47.321 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Renans Pharma Srl

Rating financiar

Financial Rating -
RENANS PHARMA SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Renans Pharma Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Renans Pharma Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Renans Pharma Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Renans Pharma Srl - CUI 23712687

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 23.862 16.160 8.554 2.175 659 10.555 19.173 15.846 22.593 40.534
Current Assets 30.536 29.432 29.417 31.212 29.043 30.428 40.593 71.022 90.206 95.155
Inventories 12.552 13.926 11.190 22.808 13.378 24.497 30.032 38.924 44.261 39.824
Receivables 17.089 8.503 13.265 7.034 9.270 5.392 9.288 30.405 34.680 34.942
Cash 896 7.004 4.961 1.369 6.395 539 1.274 1.693 11.265 20.389
Shareholders Funds -56.676 -61.746 -73.830 -84.378 -84.113 -56.536 -21.233 27.968 91.108 120.893
Social Capital 45 45 44 43 42 41 40 41 40 40
Debts 111.227 107.462 111.954 117.964 113.898 97.847 81.496 59.258 22.118 15.363
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4646 - 4646"
CAEN Financial Year 4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 95.155 euro in 2024 which includes Inventories of 39.824 euro, Receivables of 34.942 euro and cash availability of 20.389 euro.
The company's Equity was valued at 120.893 euro, while total Liabilities amounted to 15.363 euro. Equity increased by 30.294 euro, from 91.108 euro in 2023, to 120.893 in 2024.

Risk Reports Prices

Reviews - Renans Pharma Srl

Comments - Renans Pharma Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.